1. Home
  2. FEED vs MBRX Comparison

FEED vs MBRX Comparison

Compare FEED & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FEED

ENvue Medical Inc. Common Stock

HOLD

Current Price

$0.40

Market Cap

4.3M

Sector

N/A

ML Signal

HOLD

Logo Moleculin Biotech Inc.

MBRX

Moleculin Biotech Inc.

HOLD

Current Price

$0.63

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEED
MBRX
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.3M
4.3M
IPO Year
2014
2016

Fundamental Metrics

Financial Performance
Metric
FEED
MBRX
Price
$0.40
$0.63
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$61.00
AVG Volume (30 Days)
292.4K
2.2M
Earning Date
04-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$318,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.29
$0.16
52 Week High
$6.09
$7.98

Technical Indicators

Market Signals
Indicator
FEED
MBRX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
FEED
MBRX

About FEED ENvue Medical Inc. Common Stock

ENvue Medical Inc is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. It focuses on two technology platforms: the ENvue Navigation Platform, which provides an electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract; FDA 510(k) cleared for adult use, it provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Its Medical advances non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation in healthcare environments, and the company's acoustic-based therapeutic technologies.

About MBRX Moleculin Biotech Inc.

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

Share on Social Networks: